25 results on '"Silk, Ann W."'
Search Results
2. A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.
3. Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC).
4. A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).
5. Evaluating clinical responses to BRAF inhibition in BRAF/TERT promoter mutated melanoma.
6. Cyclooxygenase inhibitor use during checkpoint immunotherapy and effect on time to progression and overall survival for metastatic melanoma and non-small cell lung cancer patients.
7. Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy
8. A phase Ib study of troriluzole (BHV-4157) in combination with nivolumab.
9. Impact of the Oncology Care Model (OCM) on pain management: A retrospective cohort analysis.
10. A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
11. Cyclooxygenase inhibitor use during checkpoint blockade immunotherapy and effect on time to progression for metastatic melanoma patients.
12. Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
13. A phase I study to evaluate the safety of trigriluzole (BHV-4157) in combination with PD-1 blocking antibodies.
14. A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057).
15. Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC).
16. Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma.
17. Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients.
18. Financial impact of flat dosed (FD) monoclonal antibodies (MABs) at a single institution in 2016.
19. GRM1 to induce M-CSF and CCL2 expression to lead to an upregulation of M2 macrophages in melanoma.
20. Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.
21. First-in-human trial of ONC201 in patients with refractory solid tumors.
22. Biomarkers for Immunotherapy: Current Developments and Challenges
23. A randomized phase II study of ipilimumab induction in patients with melanoma brain metastases receiving stereotactic radiosurgery.
24. A pilot study of neoadjuvant cetuximab in locally advanced squamous cell carcinomas of skin (SCCS).
25. First-in-human dose escalation study of oral ONC201 in advanced solid tumors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.